| Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature cancer 2 (9), 891-903, 2021 | 134 | 2021 |
| Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature Cancer 2 (9), 891-903, 2021 | 61 | 2021 |
| Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways WJ Ho, R Erbe, L Danilova, Z Phyo, E Bigelow, G Stein-O’Brien, ... Genome biology 22 (1), 154, 2021 | 33 | 2021 |
| Systemic inhibition of PTPN22 augments anticancer immunity WJ Ho, S Croessmann, J Lin, ZH Phyo, S Charmsaz, L Danilova, ... The Journal of Clinical Investigation 131 (17), 2021 | 30 | 2021 |
| Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). M Yarchoan, Q Zhu, JN Durham, N Gross, S Charmsaz, JM Leatherman, ... Journal of Clinical Oncology 39 (3_suppl), 335-335, 2021 | 27 | 2021 |
| Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes WJ Ho, M Yarchoan, S Charmsaz, RM Munday, L Danilova, MB Sztein, ... JCI insight 5 (2), 2020 | 23 | 2020 |
| Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments DJ Zabransky, L Danilova, JM Leatherman, TY Lopez‐Vidal, J Sanchez, ... Hepatology 77 (5), 1566-1579, 2023 | 22 | 2023 |
| A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors S Charmsaz, N Gross, E Jaffee, WJ Ho JCI insight 6 (7), 2021 | 9 | 2021 |
| Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials DN Sidiropoulos, GL Stein-O’Brien, L Danilova, NE Gross, S Charmsaz, ... JCI insight 7 (19), 2022 | 7 | 2022 |
| Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer Y Li, RB Chang, ML Stone, D Delman, K Markowitz, Y Xue, H Coho, ... Cell Reports Medicine 5 (2), 2024 | 3 | 2024 |
| CyTOF protocol for immune monitoring of solid tumors from mouse models SM Shin, A Hernandez, E Coyne, K Munjal, NE Gross, S Charmsaz, ... STAR protocols 4 (1), 101949, 2023 | 2 | 2023 |
| Fibroblasts in the aged pancreas drive pancreatic cancer progression DJ Zabransky, Y Chhabra, ME Fane, E Kartalia, JM Leatherman, L Hüser, ... Cancer Research 84 (8), 1221-1236, 2024 | 1 | 2024 |
| Imaging mass cytometry reveals key spatial features among immune cells in hepatocellular carcinomas treated with neoadjuvant cabozantinib and nivolumab S Zhang, Q Zhu, N Gross, S Charmsaz, A Deshpande, S Xavier, A Mohan, ... Cancer Research 81 (13_Supplement), 1682-1682, 2021 | 1 | 2021 |
| Investigating peripheral blood biomarkers of immune checkpoint inhibitor associated fatigue. HL Li, S Charmsaz, SL Alden, M Brancati, A Warner, K Munjal, HL Tsai, ... Journal of Clinical Oncology 42 (16_suppl), 2571-2571, 2024 | | 2024 |
| Abstract CT016: Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of … M Baretti, L Danilova, JN Durham, CB Betts, L Cope, DN Sidiropoulos, ... Cancer Research 84 (7_Supplement), CT016-CT016, 2024 | | 2024 |
| The obesity paradox in immune checkpoint blockade: A pan-tumor analysis SL Alden, S Charmsaz, M Brancati, HL Li, A Warner, K Munjal, K Howe, ... Cancer Research 84 (6_Supplement), 3846-3846, 2024 | | 2024 |
| Highly metastatic PDAC adopts mesenchymal morphology and spatially coordinates endothelial cells with macrophages NE Gross, S Charmsaz, JW Lee, CC Huang, AG Hernandez, SM Shin, ... Cancer Research 84 (6_Supplement), 1384-1384, 2024 | | 2024 |
| PTPN22 targeting partners with 41BB/OX40 costimulation to overcome anti-PD1 resistance in pancreatic ductal adenocarcinoma S Charmsaz, NE Gross, JW Lee, J Lin, AG Hernandez, EM Coyne, ... Cancer Research 84 (6_Supplement), 5306-5306, 2024 | | 2024 |
| 1245 Th17 and Type 2 CD8+ cytokine signatures predict irAEs in solid tumors CJ Kao, S Charmsaz, M Brancati, SL Alden, HL Li, A Balaji, K Munjal, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Single cell proteomic quantification of T cell states using mass cytometry for applications in monitoring immune responses in cancer immunotherapy clinical trials DN Sidiropoulos, Z Phyo, N Gross, S Charmsaz, S Xavier, J Leatherman, ... Cancer Research 82 (12_Supplement), 1970-1970, 2022 | | 2022 |
Nicole GrossThe Johns Hopkins University School of MedicineVerified email at jhmi.edu
